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We set out to determine which characteristics and outcomes of stroke are associated with COVID-
19. 
Methods 
This case-control study included patients admitted with stroke to 13 hospitals in England and 
Scotland between 9th March and 5th July 2020.  We collected data on86strokes (81 ischaemic strokes 
and 5intracerebral haemorrhages)in patients withevidence of COVID-19 at the time of stroke onset 
(Cases).  They were compared with 1384strokes(1193 ischaemic strokes and 191 intracerebral 
haemorrhages) in patients admitted during the same time periodwho never had evidence of COVID-
19 (Controls).  In addition the whole group of stroke admissions, including another 37 in patients 
who appear to have developed COVID-19 after their stroke, were included in two logistic regression 
analyses examining which features wereindependently associated with COVID-19 status and with 
inpatient mortality. 
Results 
Cases with ischaemic stroke were more likely than ischaemic controls to occur in Asians (18.8% vs 
6.7%, p<0.0002), were more likely to involve multiple large vessel occlusions (17·9% vs 8.1%, 
p<0·03), were more severe (median NIHSS 8 vs 5, p<0·002), were associated with higher D-dimer 
levels (p<0·01) and were associated withmore severe disability on discharge (median mRS 4 vs 3, 
p<0·0001) and inpatientdeath (19.8% vs9·6%, p<0·0001).  Recurrence of stroke during the patient’s 
admission was rare in Cases and Controls (2.3% vs1.0%, NS). 
Conclusions 
Our data suggest that COVID-19 may be an important modifier of the onset, characteristics and 





































Coronavirus disease 2019 (COVID-19) ismainly recognised as a viral pneumonia, with a dry cough, 
high fever, shortness of breath and loss of taste and smell as its characteristic features1.  
Howeverthe virus responsible for this illness, severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), mayinfluence the presentation of ischaemic stroke2, although this conclusion is 
controversial3 because of a lack of high quality evidence.  In particular, the largest studies 
havecompared patients with COVID-19-associated stroke with historical controls4,5, whose strokes 
tend to be milder than those seen in contemporaneous controls6,7, resulting in a bias towards 
overestimating the influence of COVID-19 on stroke severity and any other parameters correlated 
with severity. 
Ourobjectives were to determine whether COVID-19 is associated with:a different demographic 
group; a higher proportion of ischaemic strokes; higher D-dimer values7in ischaemic strokes, as may 
be expected of a SARS-CoV-2-related hypercoagulable state8; a different distribution of stroke 
mechanisms, possibly with a predominance of large vessel occlusions9,10; more severe strokes with 
worse outcomes, including a higher inpatient mortality4,7; a higher rate of early recurrence of stroke; 
and a delay between the onset of symptoms of infection and of stroke7.  To address these objectives 
we analyseddata from a multicentre case-control study of strokes in patients admitted to 13 stroke 
services in England and Scotland during the 2020 COVID-19 pandemic. 
METHODS 
Study design and participants 
SETICOS (Service Evaluation of The Impact of COVID-19 OnStroke) is an ongoing project in 13 stroke 
centres across England and Scotland (Table S1, Supplementary Materials).  Within this project, a 
case-control study was designed and reported according to STROBE guidelines11.  Approval was given 




































confirmed that patient consent was not required for acquiring these surveillance data.  There was a 
combination of retrospective and prospective collection.  The study protocol was distributed to 
partner sites on 8th April 2020 and the first CRF was received on 14th April 2020.  Estimated 
premorbid modified Rankin scale and CT angiogram result were added to the list of fields on 29th 
April 2020 and our definition of recurrent stroke (see below) was clarified in data queries after data 
collection was complete. 
Anonymizedcase report forms (CRFs) were completed for patients admitted with a clinical diagnosis 
of stroke according to World Health Organisation criteria12.  Patients with subarachnoid 
haemorrhage were excluded.  We anticipated that most centres wouldnot be able to collect data on 
consecutive stroke admissions throughout the whole study period, so centres were asked to 
prioritise weeks during which patients with COVID-19 were admitted, and for any such week 
(Monday to Sunday) to include all strokes regardless of SARS-CoV-2 status. 
Clinical data were extracted from discharge summaries or clinical notes, blood results were taken 
from electronic results systems and CT and MR angiogram data were obtained from radiology 
reports.  Disability on discharge was determined using the modified Rankin scale (mRS)13 which 
varies from zero (no symptoms) to 6 (death).  For ischaemic strokes, the TOAST classification14was 
either taken from the discharge summary or was inferred from the clinical team’s documented 
assessment of likely stroke aetiology.  TOAST categories ‘other determined aetiology’ and 
‘undetermined aetiology’ were combined,as the choice between these two sub-groups would 
depend on whether the clinician regarded COVID-19 as a ‘determined’ cause of stroke.  Data were 
checked centrally for omissions and inconsistencies and data queries were submitted to local centres 




































Defining Cases (strokes in patients withSARS-CoV-2 at the time of stroke onset) and Controls 
For our SARS-CoV-2-positive “Case”group, we included all strokes in patients who tested positive 
within 4 days of admission(or within 4 days of their stroke for inpatient strokes), even if they were 
negative on their first test, because RT-PCR on respiratory samples has a low sensitivity for SARS-
CoV-215.  These patients would be very unlikely to have acquired the infection in hospital and turned 
PCR-positive within such a short time16.  We also includedstrokes inpatients who already had clinical 
features suspicious of COVID-19 at the time of admission and were found to be SARS-CoV-2-positive 
at any point during the first 10 daysof admission.  The “Control” group consisted of patients who 
were either consistently SARS-CoV-2-negative or were never tested because they did not show 
symptoms or signs of COVID-19.  Patients who were SARS-CoV-2 positive at some point during their 
admission but did not satisfy the criteria to be counted in the Case group were excluded from the 
case-control study but were included in the logistic regression analyses. 
Definition of recurrent stroke 
A recurrent stroke was defined as any new stroke occurring with an onset separate from that of the 
index stroke.   If a recurrent stroke occurred within 21 days of the index stroke, and was in the same 
vascular territory, then it was only included if it additionally fulfilled at least one of the following two 
criteria: 1. there was a new area of acute infarction on neuroimaging, or 2. there was a new 
intracerebral haemorrhage anatomically separate from the infarct or haemorrhage of the index 
stroke. 
Statistical methods 
The sample size was determined pragmatically by the data collection that was feasible in each centre 
during the challenging circumstances of the COVID-19 pandemic, aiming for at least 500 patients in 




































were compared between Cases and Controls using the chi-squared test, except for stroke recurrence 
rates where Fisher’s exact test was used because the expected rate of recurrent stroke in Cases was 
fewer than 5 patients.  D-dimer results were log10-transformed, resulting indistributionswhich 
approximated normal distributions, and then compared using Student’s ttest (for a difference in the 
means) and an F test (for a difference in the variances).  Other continuous variableswere compared 
using the Mann-Whitney U test. 
Binary logistic regression (Newton’s method),using demographics, vascular risk factors and stroke 
characteristics that differed between the Cases and Controls(threshold p<0·2), was used to establish 
which of thesevariables were independently associated with COVID-19 at onset.  A further binary 
logistic regression analysis examined whether COVID-19 at onset was independently associated with 
inpatient mortality, using known predictors of early mortality18 as covariates of no interest.  Where 
the admission NIHSS or estimated premorbid mRS were not recorded, the median value for that 
covariate was entered in place of the missing data and a dummy covariate of no interest was added 
to the model, assigned a value of 1 for patients where the data point was missing and 0 for all other 
patients. 
RESULTS 
Data included in the study 
We collected data from 1507stroke admissionsfrom the week commencing 9th March through to the 
week commencing 29th June, to 13 stroke centres distributed across England and Scotland (Table S1).  
Early in the study period patients were mainly tested for SARS-CoV-2 if there was clinical suspicion of 
COVID-19.  Between the weeks commencing 9th March and 11th May, however, the proportion of 
asymptomatic patients tested rose progressively from 10.3% to 93.5%, and then remained at a mean 




































Among the 123strokes in patients who were SARS-CoV-2-positive at some point, 86occurred in 
patients who had evidence of the infection at the time of stroke onset and were defined asCases 
(see Methods). Nine of these (10.4%) had no clinical features of COVID-19 during their admission.  
One Case was in a patient who had also been admitted with a previous Control stroke (without 
COVID-19) earlier during the study period.  36 patients with COVID-19 were excluded from the case-
control comparisons because they appear to have contracted the infection after their stroke (see 
Table S2 for their characteristics).  One further Case with intracerebral haemorrhage was excluded 
because the date of stroke onset could not be estimated.  The Control group consisted of 
1384strokes in 1377 patients. For 823 of these strokes the patient was negative on PCR (59.5%) and 
in 561 the patient was not tested because they never had clinical evidence of COVID-19 (40.5%).  All 
1507strokes were included in logistic regression analyses. 
Column1 Cases Controls p value 
All strokes n = 86 n = 1384   
Age: median (IQR) 74.5 (67-84) 73 (61-82) NS 
Males (%) 47 (54.7) 731 (52.8) NS 
Ischaemic (%) 81 (94.2) 1193 (86.2) 0.03 
Ethnicity n = 74 n = 1076   
White (%) 53 (71.6) 886 (82.3) 0.02 
Black (%) 7 (9.5) 98 (9.1) NS 
Asian (%) 13 (17.6) 79 (7.3) 0.002 
Mixed / other (%) 1 (1.4) 13 (1.2) NS 
Disability prior to stroke n = 84 n = 1369   
Premorbid mRS: median (IQR) 1 (0-3) 0 (0-2) 0.01 
Admission stroke severity n = 74 n = 1336   
NIHSS: median (IQR) 8 (3.25-17) 5 (2-13) 0.01 
Respiratory support during admission n = 86 n = 1369   
None required (%) 41 (47.7) 1236 (90.3) <0.00001 
O2 by nasal prongs (%) 22 (25.6) 66 (4.8) <0.00001 
O2 by mask (%) 15 (17.4) 42 (3.1) <0.00001 
Non-invasive ventilation (%) 1 (1.2) 6 (0.4) NS 
Intubation and ventilation (%) 7 (8.1) 19 (1.4) <0.00001 
Outcome measures n = 86 n = 1384   
Length of stay in days: median (IQR) 7 (3-17) 3 (2-8) <0.00001 
mRS on discharge: median (IQR) 4 (2-5) 3 (1-4) 0.0004 
Death during admission (%) 17 (19.8) 133 (9.6) 0.01 




































Table 1.Stroke characteristics in Cases (with evidence of COVID-19 at stroke onset) and Controls (with no 
evidence of COVID-19 at any time), including ischaemic and haemorrhagic strokes.  IQR: interquartile range; 




































  Ischaemic strokes Intracerebral haemorrhages 
Column1 Cases Controls p value Cases2 Controls2 p value  
All strokes n = 81 n = 1193   n = 5 n = 191   
Age: median (IQR) 74 (67-85) 73 (61-83) NS 76 (67-80) 73 (61-80) NS 
Male (%) 44 (54.3) 633 (53.1) NS 3 (60) 98 (51.3) NS 
Intravenous tPA (%) 10 (12.5) 185 (15.5) NS       
Thrombectomy (%) 1 (1.3) 71 (6) NS       
Ethnicity n = 69 n = 939   n = 5 n = 137   
White (%) 48 (69.6) 785 (83.6) 0.003 5 (100) 101 (73.7) NS 
Black (%) 7 (10.1) 80 (8.5) NS 0 (0) 18 (13.1) NS 
Asian (%) 13 (18.8) 63 (6.7) 0.0002 0 (0) 16 (11.7) NS 
Mixed / other (%) 1 (1.4) 11 (1.2) NS 0 (0) 2 (1.5) NS 
Admission stroke severity n = 70 n = 1159   n = 4 n = 177   
NIHSS: median (IQR) 8 (3.25-11) 5 (2-11) 0.002 9 (3.25-14.25) 10 (4-20) NS 
TOAST category n = 72 n = 1156         
Large vessel atherosclerosis (%) 11 (15.3) 193 (16.7) NS       
Cardioembolic (%) 23 (31.9) 291 (25.2) NS       
Small vessel (%) 18 (25.0) 227 (19.6) NS       
Other (%) 20 (27.8) 445 (38.5) NS       
Fever/cough/SOB onset date n = 45     n = 3     
[Symptom onset] - [stroke onset]: 
median in days (IQR) -6 (-14 - 0)     +4 (+3 - +4)     
CT or MR angiogram n = 39 n = 627         
No LVO (%) 23 (59.0) 362 (57.7) NS       
Single LVO (%) 9 (23.1) 214 (34.1) NS       
Multiple LVO (%) 7 (17.9) 51 (8.1) 0.03       
Full blood count n = 81 n = 1173   n = 5 n = 188   
NLR: median (IQR) 4.7 (3.1-8.3) 3.3 (2.2-5.8) 0.00005 5.2 (3.7-8.9) 3.9 (2.2-7) NS 
Platelets: median (IQR) 251 (185-342) 241* (200.5-293) NS 273 (230-275) 232 (185-293) NS 
CRP n = 78 n = 1051   n = 5 n = 162   
CRP (mg/litre): median (IQR) 29.8 (7.4-114.9) 5 (1.9-14.3) <0.00001 2.9 (1.6-5.2) 5 (2-13) NS 
D-dimer n = 23 n = 177         
Log10 [D-dimer, ng/ml]: mean (SE) 3.4 (0.20) 3.0 (0.04) 0.01       
Outcome measures n = 81 n = 1193   n = 5 n = 191   
Length of stay in days: median (IQR) 7 (3-17) 3 (2-7) <0.00001 9 (7-11) 5 (2-10) NS  
mRS on discharge: median (IQR) 4 (2-5) 3 (1-4) 0.00003 4 (3-4) 4 (3-6) NS 
Death during admission (%) 16 (19.8) 82 (9.6) 0.00003 1 (20) 51 (26.7) NS 
Recurrence during admission (%) 2 (2.5) 12 (1.0) NS 0 (0.0) 2 (1.0) NS 
Table 2.Comparisons between Cases and Controlsshown separately for ischaemic strokes (blue columns) and intracerebral 
haemorrhages (red columns). IQR: interquartile range;NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin 
scale;NLR: neutrophil-to-lymphocyte ratio;SE: standard error.  For [symptom onset – stroke onset], a negative value indicates that 




































Demographics and stroke characteristics 
Ethnicity was recorded in 86.0% of Cases and 77.7% of Controls.  The proportion of Asian patients 
among Cases (17.6%) was more than twice that seen in the Controls (7.3%, p<0.002, Table 1), a 
disparity entirely attributable to the difference found in the ischaemic stroke group (18.8% vs 6.7%, 
p<0.0002, Table 2). There was a correspondingly lower proportion of White patients among Cases 
(Table 1 and Supplementary Figure S1).  There was no significant difference in the proportion of 
Black patients between the two groups.  Age and sex also did not differ between the two groups 
(Supplementary Figure S2 and Table 1). 
There was a higher proportion of ischaemic strokes in the Cases (94.2%) compared with the Controls 
(86.2%, p=0.03).  Among ischaemic strokes that were classified according to TOAST criteria14, there 
were no significant differences in the proportions of stroke attributed to large vessel atherosclerosis, 
cardioembolism or small vessel disease (Table 2). 
D-dimers 
In the patients with ischaemic stroke, D-dimers were measured in 23/81 (28·4%) of Casesand 
177/1193 (14.8%) of Controls; the distributions are shown on a log10 scale in Figure 1.  Treating the 
two distributions in Figure 1 as normal distributions of potentially differing variance, the Cases had a 
significantly higher mean log10 D-dimer (3·4) compared with the Controls (3·0, p<0·01) and also a 
higher variance (standard deviation 0·83 vs 0·63, p<0·03), i.e. there was a broader distribution of D-
dimers in Cases, rather than a rightward shift of the whole curve. 
Timing of COVID-19 and stroke onsets 
In the 44 Cases with ischaemic stroke in whom both dates were recorded, the onset of the COVID-
19-relevant symptoms of fever, cough or dyspnoea occurred a median of6 days before the stroke 




































dates recorded, the COVID-19 symptoms occurred a median of 4 days after the stroke onset, and 
although the numbers are small, the difference between these two medians was significant 
(p<0.002). 
Stroke severity on admission 
Figure 2 shows the distributions of ischaemicstroke severities on admission for Cases and Controls, 
measured using the NIHSS.  Ischaemic strokes were significantly more severe in the Cases(median 
NIHSS = 8) than the Controls (median NIHSS = 5, p<0·002).  In patients with intracerebral 
haemorrhage, however, we did not find any significant difference in stroke severity between the two 
groups (median NIHSS = 9 and 10, Table 2). 
Intracranial large vessel occlusion 
Among patients with ischaemic stroke, aCT or MR angiogram was available in 39/81 Cases (48·1%) 
and 627/1193 Controls (52.6%).  The proportion of patients with at least one intracranial large vessel 
occlusion (LVO) was not significantly different between Casesand Controls, whether expressed as a 
proportion of the patients who had this imaging done (41.0% vs 42.3%) or as a proportion of the 
whole stroke group (19.7% vs 22.2%).  However, of the patients who had CT or MR angiography, the 
proportion of Cases with multiple intracranial LVOs (17·9%) was more than twice that seenin 
Controls (8.1%,p<0·03;Figure 3). 
Features independently associated with COVID-19 status 
We used binary logistic regression to assess which demographics, vascular risk factors and stroke 
characteristics recorded on admission were independently associated with COVID-19 at stroke 
onset.  Asian ethnicity and multiple intracranial large vessel occlusions on CT or MR 
angiographywere independently associated with COVID-19 at stroke onset, whilst premorbid mRS 




































not significantly affected by omission of the 37 patients who developed COVID-19 but did not fulfil 
the criteria for Cases. 
  Odds ratio 95% CI p-value 
Asian 2.70 1.38 5.30 0.004 
> 1 LVO 2.62 1.11 6.15 0.03 
Premorbid mRS 1.16 0.99 1.35 0.07 
Current smoker 0.50 0.21 1.19 0.12 
Admission NIHSS 1.02 0.99 1.05 0.14 
Type 2 diabetes 1.28 0.77 2.12 0.34 
Table 3.Binary logistic regression analysis to explore the association of demographics, vascular risks factors 
and stroke characteristics on admission with COVID-19 at the time of stroke.   Covariates are shown in order of 
statistical significance.  CI: confidence intervals; >1 LVO: more than one large-vessel occlusion. 
Outcome from stroke 
Stroke recurrence during admission was very rare in Cases (2.3%) and in Controls (1.0%) and with 
such small numbers it was not possible to demonstrate any significant difference between these 
groups, whether we included all strokes (Table 1) or just ischaemic strokes (Table 2).  The rates in 
Cases and Controls are in any case not directly comparable as Cases had a longer median length of 
stay (Table 1). 
The proportion ofischaemic strokesresulting in death during admission was significantly higher in 
Cases(19.8%) than in Controls (9·6%, p<0·00003, Table 2) and the median mRS on discharge was 
higher in ischaemic Cases(median mRS = 4) than in ischaemic Controls (median mRS = 3, p<0·00003, 
Figure 4).  Among intracerebral haemorrhages, we were unable to demonstrate any significant 
difference in disability or mortality between the 5Cases (median mRS = 4, mortality 20.0%) and the 
191 Controls (median mRS 4, mortality 26.7%).  COVID-19 at the onset of the stroke was 
independently associated with death during admission, even after correction for parameters known 




































  Odds ratio 95% CI p-value 
Admission NIHSS 1·16 1·13 1·19 <0·00001 
Intracerebral haemorrhage 3·19 1.99 5·11 <0·00001 
Age (per year) 1·03 1·01 1·04 0·002 
Ischaemic heart disease 1·92 1·21 3·02 0·005 
COVID-19 at stroke onset 2.11 1.08 4.13 0·03 
Premorbid mRS 1·12 0·98 1·30 0·11 
Type 2 diabetes mellitus 1·37 0·86 2·19 0·19 
Small vessel ischaemic stroke 0.64 0·29 1·42 0·27 
Table 4.Binary logistic regression analysis demonstrating that COVID-19 at stroke onset is associated with 
inpatient mortality even after correction for other clinical features known to be predictors of early mortality 
(18).CI: confidence interval; NIHSS: National Institutes of Health Stroke Scale; ICH: intracerebral haemorrhage. 
DISCUSSION 
ThisUK-based multicentre study provides a large case-control comparison, with contemporaneous 
controls,of strokes with and without COVID-19.  Ischaemic strokes which were associated with 
COVID-19 at onset were:more likely to occur in Asian people; more likely to involve multiple large 
vessel occlusions; more severe; associated with higher D-dimer levels; and more likely to have a 
worse functional outcome or result in death.  These findings add substantially to the previous 
smaller and methodologically limited studies,summarised in a recent systematic review2, to confirm 
that COVID-19 has an important influence over the onset, characteristics and outcome of acute 
ischaemic stroke. 
Previous case series suggested that COVID-19 may be associated with a higher proportion of strokes 
with large vessel occlusions2,9,10and this conclusion was confirmed in a single case-control study19.  In 
our study, by contrast,the overall incidence of at least one large vessel occlusion was the same in the 
Case and Control groups.  The proportion of Cases with multiple large vessel occlusions, however, 
was more than twice that seen in the Control group. 
Large vessel occlusion in COVID-19 may be a direct manifestation of a SARS-CoV-2-related 




































log10D-dimer higher in Cases than in Controls, but also the variance of log10 D-dimers was higher in 
Cases, suggesting greater heterogeneity in this group; one potential explanation would be the 
presence of a sub-group with higher D-dimers associated with a SARS-CoV-2-related coagulopathy. 
Our finding that ischaemic stroke associated with COVID-19 is more severe than in patients without 
COVID-19 is consistent with asmall case-control study from New York, which reported more severe 
strokes in 32 patients with COVID-19 (median NIHSS = 19) than in 46 contemporaneous control 
patients without the infection (median NIHSS = 8)7.  However, strokes in theircontemporaneous 
control group were considerablymore severe thanthey were in their historical controls (median 
NIHSS = 3).  The difference presumably reflects a strong tendency for patients with minor stroke to 
stay away from hospital during the pandemic, or for doctors to avoid admitting them.  Although we 
have observed the same effect in the UK6, the degree of exclusion of minor strokes during the 
pandemic appears to have been less pronouncedin our study (Control groupmedian NIHSS = 5).  This 
disparity may reflect differences in public behaviour during the pandemic in different populations, or 
differences in admission strategies between the group of UKhospitals included in our study and the 
private healthcare organisation (NYU Langone Health) in the New York study. 
The shift towards greater stroke severity in COVID-19-negative patientsduring the pandemic6means 
that registry studies comparing cases of COVID-19-associated stroke with historical controls4,5are 
biased towards overestimating any influence of COVID-19 on stroke severity, and other correlated 
parameters such as the incidence of large vessel occlusions and inpatient mortality rate, because 
historical controls have milder strokes than contemporaneous controls7.We have avoided this bias 
by comparing our COVID-19 Cases with contemporaneous Controls.  Even so, outcomes were still 
worse in Cases than Controls in our study, and in particular theinpatient mortality rate in our 
Caseswas significantly higher, a finding that remained after correction for other known risk factors 




































We found no evidence to support previous suggestions that SARS-CoV-2 infection may be associated 
with a younger age7,10 or male sex7 in stroke patients.  In the case-control study from New York7, by 
contrast, patients with COVID-19-associated strokes were younger (median 63 years) than controls 
(70 years).  Most of their patients with COVID-19-associated stroke presented with COVID-19 as their 
primary diagnosis, so alikelyexplanation for this disparity is that, in their study, older patients with 
COVID-19 as their primary diagnosis may have beenless likely to present and be admitted to hospital 
during the pandemic than younger patients. 
There was a median delay of 6 days from the onset of COVID-19 symptoms to the onset of ischaemic 
stroke, perhaps corresponding to the reported delay between COVID-19 onset and the development 
of a hypercoagulable state8.  However, COVID-19 does not appear to influence stroke solely through 
a single mechanism; no single aetiological category of ischaemic stroke seems to have been 
morestrongly associated with COVID-19 infection than the others.  Wesuggest that COVID-19 may 
provoke the onset of an ischaemic stroke through a variety of thrombotic and inflammatory 
mechanisms, promoting generation of thrombus in the heart20 or large vessels10,21 or via small vessel 
occlusion22.  Which of these mechanisms manifests in a given patient may be determined by 
thatindividual’s conventional vascular risk factors such as atrial fibrillation, large vessel atheroma, 
hypertensionor type 2 diabetes mellitus. 
Strengths of our study are that we included patients from 13 centres across the UK, so our results 
may be more representative of the overall stroke population than existing studies from a single 
hospital system or city.  The use of contemporaneous controls allowed us to draw conclusions about 
the influence of COVID-19 on stroke severity, mortality and the incidence of large vessel occlusion, 
inferences that cannot be made in studies comparing registry data with historical controls.  In 
addition the study was conducted according to a protocol agreed upon early in the pandemic, before 




































The main limitation of this study is thatwe were only able to report investigations done as part of 
routine clinical care.  Some reports or tests were not available in all patients, which could introduce 
reporting or indication biases.  For example, if there were a higher rate of reporting of ethnicity in 
Cases compared Controls only in Asians, thisreporting bias could in theory have exaggerated the 
association between Asian patients and COVID-19, although such a specific reporting bias seems 
implausible. 
D-dimers were measured in a higher proportion of Cases (28.4%) than Controls (14.8%), suggesting 
that the criteria for measuring them may have been narrower in the Control group.  Assuming that 
narrower test criteria select patients with higher D-dimers, there may have been a bias towards 
higher D-dimers in Controls, resulting in an underestimate of the difference in D-dimers between the 
two groups.  Although an indication bias could also have operated in the selection of patient for CT 
angiography, reassuringly we found no evidence of any bias towards performing this imaging in 
patients withCOVID-19. 
Not all Control patients were tested for SARS-CoV-2, so this group may have included patients with 
asymptomatic infection.  In addition, we were reliant on SARS-CoV-2 RT-PCR results from respiratory 
swabs for COVID-19 diagnosis and this test has a very poor sensitivity16.  However, the large size of 
our Control group will have minimized the influence of false-negative COVID-19 results over this 
group. 
If patients with minor stroke were more likely to attend if they had symptoms of COVID-19, then this 
effect could have reduced the median NIHSS in Cases, causing us to underestimate the difference in 
stroke severity between Cases and Controls.  Finally some COVID-19-associated strokes may have 





































Our study provides the most compelling evidence yet that COVID-19-associated ischaemic strokes 
are more severe and more likely to result in severe disability or death, although the outlook is not 
quite as bleak as previous studies have suggested7,8.  Our results suggest the following 
recommendations for management of stroke patients during the ongoing COVID-19 pandemic. 
If at any point a stroke centreis not routinely testing all stroke admissions for SARS-CoV-2, patients 
presenting with ischaemic stroke and very elevated D-dimers with no other explanation should be 
considered for testing,even if the clinical suspicion of COVID-19 is otherwise low.  Criteria for 
requesting CT angiography in stroke patients may now need to take account of their COVID-19 
status, because the finding of multiple large vessel occlusions may require a specific management 
strategy such as mechanical thrombectomy or possibly, in the future, a different antithrombotic 
agent.  On the other hand, in most patients with COVID-19-associated ischaemic stroke, very early 
anticoagulation is probably not warranted as a strategy to prevent inpatient stroke recurrence, as 
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FIGURE LEGENDS (colour versions) 
Figure 1.Distribution of D-dimers (in ng/ml), in Cases (red curve) and Controls (blue curve) with 
ischaemic stroke, plotted on a log10 scale.  Bin width of log10 D-dimer = 0.25.  Value shown on X axis is 
the lower value of each bin.  The value on the Y axis is the percentage of D-dimer results falling 
within that range of values.  Each red arrow indicates one Case who was anticoagulated for a DVT or 
PE during their admission, and each blue arrow a Control who was anticoagulated for this indication. 
Figure 2.Distributions of NIHSS scores in Cases(red bars) and Controls(blue bars)with ischaemic 
stroke.For each NIHSS range, the frequency of Cases is shown as a percentage of the Cases in which 
the NIHSS was measured, and similarly for Controls.  NIHSS: National Institutes of Health Stroke 
Scale.  Bin width = 2. 
Figure 3.Relationship between CTor MR angiogram findings and COVID-19 statusin patients with 
ischaemic stroke.  For Cases and Controls, dark blue bars show the proportion of those scanned in 
whom more than one intracranial large vessel occlusion (LVO) was reported, mid blue bars show the 
proportion in whom only one LVO was reported, and pale blue bars show the proportion in whom 
no LVO was reported. 
Figure 4.The distribution of modified Rankin (mRS) scores on discharge in Cases and Controls with 
ischaemic stroke.  The mRS indicates the degree of disability: for example zero (in the palest blue) 
represents no symptoms, 1 represents symptoms without disability, 5represents severe disability 





































FIGURE LEGENDS (monochrome versions) 
Figure 1.Distribution of D-dimers (in ng/ml), in Cases (black circles) and Controls (grey triangles) with 
ischaemic stroke, plotted on a log10 scale.  Bin width of log10 D-dimer = 0.25.  Value shown on X axis is 
the lower value of each bin. Each black arrow indicates one Case who was anticoagulated for a DVT 
or PE during their admission, and each grey arrow a Control who was anticoagulated for this 
indication. 
Figure 2.Distributions of NIHSS scores in Cases (black bars) and Controls (grey bars) with ischaemic 
stroke.  For each NIHSS range, the frequency of Cases is shown as a percentage of the Cases in which 
the NIHSS was measured, and similarly for Controls.  NIHSS: National Institutes of Health Stroke 
Scale.  Bin width = 2. 
Figure 3.Relationship between CT angiogram findings and COVID-19 status in patients with ishaemic 
stroke.  For Cases and Controls who had a CT or MR angiogram, black bars show the proportion in 
whom more than one intracranial large vessel occlusion (LVO) was reported on CT, dark grey bars 
show the proportion in whom only one LVO was reported, and light grey bars show the proportion in 
whom no LVO was reported. 
Figure 4.The distribution of modified Rankin (mRS) scores on discharge in Cases and Controls with 
ischaemic stroke.  The mRS indicates the degree of disability: for example zero (white) represents no 
symptoms, 1 represents symptoms without disability, 5 represents severe disability and 6 (black) 
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